Inclusion Criteria:

- Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma
(DLBCL).

- Stable disease or better for at least 3 months on most recent treatment

- Have not received any chemotherapy, radiation therapy, major surgery, or any other
investigational therapy for at least 4 weeks prior to entry in this study

- Adequate blood testing, liver, and kidney function as required by the study.

- Eligible subjects will allow tissue samples to be examined and stored.

Exclusion Criteria:

- Patient has been treated with other investigational agents with a similar anti-tumor
mechanism.

- Patient should not have failed more than 3 prior treatment regimens.